This invention provides a compound having the structure wherein A is a ring structure, with or without substitution; Z is present or absent and when present is wherein n is 0, 1, 2, 3, or 4; Y is —(CR11R12)—, —NH(CR11R12)—, or —O(CR11R12)—, wherein R11 and R12 are each hydrogen or combine to form a carbonyl; R1, R2, R3, R4, R5 and R6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester or amide; α represents a bond, which is present or absent and when α is present, then R7 and R8 are absent; R7 and R8 are present when α is absent and are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester, amide or R5 and R7 combine to form a carbonyl or R6 and R8 combine to form a carbonyl; R9 and R10 are each hydrogen or combine to form a carbonyl; and when α is present, Z is where n=1, Y is —(CR11R12)— where R11 and R12 are H, A is unsubstituted indole attached at the 3-position of the indole, R3, R4, R5, R6, R9 and R10 are each H, and one of R1 or R2 is H, then the other one of R1 or R2 is other than H or ethyl, or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof.
Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disorders